The antiplatelet drug cangrelor bested clopidogrel in the CHAMPION PHOENIX trial, which found fewer ischemic complications when cangrelor was used in percutaneous coronary intervention. The results were presented at the American College of Cardiology meeting. However, SCAI fellow Dr. Ajay Kirtane of Columbia University Medical Center warned against extrapolating the findings. "I think it really depends on the patient population. I don't think you can extrapolate these data to patients that get preloading," said Kirtane, who noted that in some clinical settings, the new drug could offer opportunities for cost savings.
Published in Brief: